Population pharmacokinetic analysis and dosing regimen optimization of eravacycline in critically ill patients with carbapenem-resistant Acinetobacter baumannii pneumonia
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag178 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Luqi Lou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou 350001, People's Republic of China. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Anti-Bacterial Agents, Acinetobacter Infections, Tetracyclines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Joint Funds for the Innovation of Science and Technology, Fujian province.
Abstract (Originalsprache)
Objectives
To develop a population pharmacokinetic (PopPK) model of eravacycline in critically ill patients with carbapenem-resistant Acinetobacter baumannii (CRAB) pneumonia, characterize its pharmacokinetic profile, and optimize dosing regimens to ensure adequate drug exposure in this vulnerable population.
Methods
The plasma concentration of eravacycline was determined using liquid chromatography-tandem mass spectrometry. PopPK analysis was performed using nonlinear mixed-effects modelling, and the optimal dosing regimen was optimized via Monte Carlo simulation.
Results
A total of 104 plasma samples were collected from 18 patients for eravacycline concentration determination. The final PopPK model was a two-compartment model with body weight as a significant covariate on peripheral volume of distribution (V2). The population typical values for CL, central volume of distribution (V1) and V2 in the final model were 14.4 L/h, 177.6 L and 383.2 L, respectively. Monte Carlo simulations demonstrated that the PK/PD target for eravacycline was achievable with a standard dose (1 mg/kg, Q12 h) at an MIC of 0.125 mg/L in patients weighing 41–80 kg. However, this fixed-dosing strategy was suboptimal at higher MICs.
Conclusions
This study successfully developed the first PopPK model for eravacycline in critically ill patients with CRAB pneumonia. The findings highlight substantial pharmacokinetic variability and demonstrate that weight-based dosing is crucial to ensure effective exposure, underscoring the necessity of PK/PD-guided personalized therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou 350001, People's Republic of China.
- College of Pharmacy, Fujian Medical University, Fuzhou 350004, People's Republic of China.
- Department of Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou 350001, People's Republic of China.
ORCID-Profile: Xueyong Li, Xuemei Wu
Förderung
- Joint Funds for the Innovation of Science and Technology, Fujian province
Zitieren
APA
Lou, L., Xiao, Y., Wang, L., Li, X., Wu, J., Lin, T., Wu, X., Xie, H., Que, W., Zhang, H., Qiu, H., & Cheng, Y. (2026). Population pharmacokinetic analysis and dosing regimen optimization of eravacycline in critically ill patients with carbapenem-resistant Acinetobacter baumannii pneumonia. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag178
Vancouver
Lou L, Xiao Y, Wang L, Li X, Wu J, Lin T, et al. Population pharmacokinetic analysis and dosing regimen optimization of eravacycline in critically ill patients with carbapenem-resistant Acinetobacter baumannii pneumonia. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag178
BibTeX
@article{Lou2026,
author = {Lou, Luqi and Xiao, Ying and Wang, Linyao and Li, Xueyong and Wu, Junnan and Lin, Tian and Wu, Xuemei and Xie, Helin and Que, Wancai and Zhang, Hui and Qiu, Hongqiang and Cheng, Yu},
title = {Population pharmacokinetic analysis and dosing regimen optimization of eravacycline in critically ill patients with carbapenem-resistant Acinetobacter baumannii pneumonia},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag178}
}
EUVIMED